Oxford vaccine produces “double defence” against SARS-CoV-2 – Seeking Alpha

AZN up 3% after hours.

Londons Telegraph reports that arises from a Phase 1 clinical trial assessing Oxford Universitys COVID-19 vaccine prospect ChAdOx1 nCoV-19 [ADZ1222 by licensee AstraZeneca (NYSE: AZN)] in healthy volunteers showed that it set off a “double defense” immune reaction versus the SARS-CoV-2 infection.

Researchers noted that administration of the prospect produced both antibodies and killer T cells. The reaction, if verified, has considerable ramifications for continual resistance since antibodies may fade away within months while T cells stay in flow for many years.